Evicenter
Keytruda (pembrolizumab) in High-risk early-stage triple-negative breast cancer
Manufacturer
Merck Sharp & Dohme LLC
Prescribing information
Keytruda (opens in a new tab)
Questions
28
Last updated

All questions

Safety: Keytruda (pembrolizumab) in high-risk early-stage triple-negative breast cancer

5 questions · 1 source

Safety

What are KEYTRUDA side effects with chemotherapy in early-stage TNBC (KEYNOTE-522)?

“In KEYNOTE-522, when KEYTRUDA was administered with neoadjuvant chemotherapy (carboplatin and paclitaxel followed by doxorubicin or epirubicin and cyclophosphamide) followed by surgery and continued adjuvant treatment with KEYTRUDA as a single agent (n=778) to patients with newly diagnosed, previously untreated, high-risk early-stage TNBC, fatal adverse reactions occurred in 0.9% of patients, including 1 each of adrenal crisis, autoimmune encephalitis, hepatitis, pneumonia, pneumonitis, pulmonary embolism, and sepsis in association with multiple organ dysfunction syndrome and myocardial infarction. Serious adverse reactions occurred in 44% of patients receiving KEYTRUDA; those ≥2% were febrile neutropenia (15%), pyrexia (3.7%), anemia (2.6%), and neutropenia (2.2%). KEYTRUDA was discontinued in 20% of patients due to adverse reactions. The most common reactions (≥1%) resulting in permanent discontinuation were increased ALT (2.7%), increased AST (1.5%), and rash (1%). The most common adverse reactions (≥20%) in patients receiving KEYTRUDA with chemotherapy followed by KEYTRUDA alone were fatigue (70%), nausea (67%), alopecia (61%), rash (52%), constipation (42%), diarrhea and peripheral neuropathy (41% each), stomatitis (34%), vomiting (31%), headache (30%), arthralgia (29%), pyrexia (28%), cough (26%), abdominal pain (24%), decreased appetite (23%), insomnia (21%), and myalgia (20%).” (opens the source at this quote in a new tab)

How are KEYTRUDA immune-mediated side effects managed?

How does KEYTRUDA cause immune-mediated side effects?

Can KEYTRUDA cause liver problems (immune-mediated hepatitis)?

Monitoring

What lab monitoring does KEYTRUDA require in early-stage TNBC?